Prikaz osnovnih podataka o dokumentu
Soluble sPD-L1 and serum amyloid A1 as potential biomarkers for lung cancer
dc.creator | Jovanović, Dragana | |
dc.creator | Roksandić-Milenković, Marina | |
dc.creator | Kotur-Stevuljević, Jelena | |
dc.creator | Ceriman, Vesna | |
dc.creator | Vukanić, Ivana | |
dc.creator | Samardžić, Natalija | |
dc.creator | Popević, Spasoje | |
dc.creator | Ilić, Branislav | |
dc.creator | Gajić, Milija | |
dc.creator | Simon, Marioara | |
dc.creator | Simon, Ioan | |
dc.creator | Spasojević-Kalimanovska, Vesna | |
dc.creator | Belić, Milica | |
dc.creator | Mirkov, Damjan | |
dc.creator | Šumarac, Zorica | |
dc.creator | Milenković, Vladislav | |
dc.date.accessioned | 2019-09-02T12:11:04Z | |
dc.date.available | 2019-09-02T12:11:04Z | |
dc.date.issued | 2019 | |
dc.identifier.issn | 1452-8258 | |
dc.identifier.uri | https://farfar.pharmacy.bg.ac.rs/handle/123456789/3341 | |
dc.description.abstract | Background: The objective of this prospective study was to evaluate whether soluble programmed cell death-1/programmed cell death-ligand 1 (PD-1/PD-L1) and serum amyloid A1 (SAA1) are potential diagnostic, predictive or prognostic biomarkers in lung cancer. Methods: Lung cancer patients (n=115) with advanced metastatic disease, 101 with non-small cell lung cancer, NSCLC (77 EGFR wild-type NSCLC patients on chemotherapy, 15 EGFR mutation positive adenocarcinoma patients, 9 patients with mPD-L1 Expression >= 50% NSCLC - responders to immunotherapy), and 14 patients with small cell lung cancer (SCLC) were examined. ELISA method was used to determine sPD-L1 and SAA1 concentrations in patients' plasma. Results: Significantly higher blood concentrations of sPD-L1 and SAA1 were noted in lung cancer patients compared with a healthy control group. In PD-L1 + NSCLC patients, a significantly higher sPD-L1 level was noticed compared to any other lung cancer subgroup, as well as the highest average SAA1 value compared to other subgroups. Conclusions: It seems that sPD-1/PD-L1 might be a potential biomarker, prognostic and/or predictive, particularly in patients treated with immunotherapy. Serum amyloid A1 has potential to act as a good predictor of patients' survival, as well as a biomarker of a more advanced disease, with possibly good capability to predict the course of disease measured at different time points. | en |
dc.publisher | Društvo medicinskih biohemičara Srbije, Beograd i Versita | |
dc.relation | info:eu-repo/grantAgreement/MESTD/Basic Research (BR or ON)/175046/RS// | |
dc.rights | openAccess | |
dc.source | Journal of Medical Biochemistry | |
dc.subject | sPD-L1 | en |
dc.subject | serum amyloid A1 | en |
dc.subject | biomarker | en |
dc.subject | PD-L1 positive NSCLC | en |
dc.title | Soluble sPD-L1 and serum amyloid A1 as potential biomarkers for lung cancer | en |
dc.type | article | |
dc.rights.license | ARR | |
dcterms.abstract | Роксандић-Миленковић, Марина; Илић, Бранислав; Јовановић, Драгана; Котур-Стевуљевић, Јелена; Вуканић, Ивана; Миленковић, Владислав; Цериман, Весна; Симон, Иоан; Спасојевић-Калимановска, Весна; Попевић, Спасоје; Мирков, Дамјан; Гајић, Милија; Самарджић, Наталија; Белић, Милица; Симон, Мариоара; Шумарац, Зорица; | |
dc.citation.volume | 38 | |
dc.citation.issue | 3 | |
dc.citation.spage | 332 | |
dc.citation.epage | 341 | |
dc.citation.other | 38(3): 332-341 | |
dc.citation.rank | M23 | |
dc.identifier.wos | 000468363100011 | |
dc.identifier.doi | 10.2478/jomb-2018-0036 | |
dc.identifier.pmid | 31156344 | |
dc.identifier.scopus | 2-s2.0-85057603105 | |
dc.identifier.fulltext | https://farfar.pharmacy.bg.ac.rs//bitstream/id/1905/3339.pdf | |
dc.type.version | publishedVersion |